Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma | Completed
Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma
Health Conditions
  • Brain and Central Nervous System Tumors
Completed
Recruitment Status
NCT00004224
Primary Trial ID Number
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying combination chemotherapy and radiation therapy to see how well they work in treating children with localized ependymoma.
Primary Outcome Measures
  • Event-free survival; null; Overall survival; null; Surgical operability; null; Response rate; null
Secondary Outcome Measures
    Sorry, this information is not available
Research Question
  • RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying combination chemotherapy and radiation therapy to see how well they work in treating children with localized ependymoma.
Design Type
Sorry, this information is not available
Ethics Approval
Sorry, this information is not available
Publications
Sorry, this information is not available
Countries of Recruitment
Argentina; Canada; Italy; Netherlands; Spain; Sweden; United Kingdom
Participant Sex
Both
Participant Age Range
3 Years to 20 Years
Participant Type
Sorry, this information is not available
Trial Sample Size
65
Participant Inclusion Criteria
  • DISEASE CHARACTERISTICS:
  • - Histologically proven nonmetastatic intracranial ependymoma
  • - Cellular
  • - Papillary
  • - Clear cell
  • - Mixed cell
  • - Anaplastic
  • - No myxopapillary ependymoma, subependymoma, or ependymoblastoma
  • PATIENT CHARACTERISTICS:
  • Age:
  • - 3 to 20
  • Performance status:
  • - Not specified
  • Life expectancy:
  • - Not specified
  • Hematopoietic:
  • - No hematologic disease that would preclude study participation
  • Hepatic:
  • - Not specified
  • Renal:
  • - No renal disease that would preclude study participation
  • Other:
  • - No concurrent unrelated disease that would preclude study participation
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy:
  • - Not specified
  • Chemotherapy:
  • - No prior chemotherapy
  • Endocrine therapy:
  • - Prior steroids allowed
  • Radiotherapy:
  • - No prior radiotherapy
  • Surgery:
  • - Not specified
Participant Exclusion Criteria
  • DISEASE CHARACTERISTICS:
  • - Histologically proven nonmetastatic intracranial ependymoma
  • - Cellular
  • - Papillary
  • - Clear cell
  • - Mixed cell
  • - Anaplastic
  • - No myxopapillary ependymoma, subependymoma, or ependymoblastoma
  • PATIENT CHARACTERISTICS:
  • Age:
  • - 3 to 20
  • Performance status:
  • - Not specified
  • Life expectancy:
  • - Not specified
  • Hematopoietic:
  • - No hematologic disease that would preclude study participation
  • Hepatic:
  • - Not specified
  • Renal:
  • - No renal disease that would preclude study participation
  • Other:
  • - No concurrent unrelated disease that would preclude study participation
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy:
  • - Not specified
  • Chemotherapy:
  • - No prior chemotherapy
  • Endocrine therapy:
  • - Prior steroids allowed
  • Radiotherapy:
  • - No prior radiotherapy
  • Surgery:
  • - Not specified
Interventions
Drug; cyclophosphamide; null; []; Drug; etoposide; null; []; Drug; vincristine sulfate; null; []; Procedure; adjuvant therapy; null; []; Procedure; conventional surgery; null; []; Radiation; radiation therapy; null; []
Design Details
Sorry, this information is not available
Study Design
Primary Purpose: Treatment
Results Reporting
Sorry, this information is not available
Acronym
Sorry, this information is not available
Scientific Title
SIOP Study of Combined Modality Treatment in Childhood Ependymoma
Secondary Trial Identifying Number
SIOP-EPENDYMOMA-99; AIEOP-EPENDYMOMA-99; CCLG-EPENDYMOMA-99; EU-99001
Website
http://cancer.gov/clinicaltrials/SIOP-EPENDYMOMA-99
Study Funded By
Societe Internationale d'Oncologie Pediatrique
Funder Type
Sorry, this information is not available
Study Sponsored By
Societe Internationale d'Oncologie Pediatrique
Study Also Sponsored By
Children's Cancer and Leukaemia Group; Italian Association for Pediatric Hematology Oncology
Primary Sponsor Type
Sorry, this information is not available
Secondary Sponsor Type
Sorry, this information is not available
Key Dates

Date of First Enrollment
Date Not Available
Recruitment End Date
Date Not Available
Trial End Date
Date Not Available
Date added to Registry

28 Jan 2000

Last Updated

23 Aug 2013

Date Record Refreshed on UKCTG

01 Aug 2015